Changes in Brain Activity Associated With Upper Limb Motor Recovery

NCT ID: NCT02325427

Last Updated: 2022-04-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-11-30

Study Completion Date

2020-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is to investigate changes in brain activities in acute stroke patients , and to correlate findings with clinical outcome measures. Another aim of the study is to investigate whether transcranial direct current stimulation (tDCS) could improve motor function in subjects with poor brain activity after stroke. The brain activity will be measured by single and paired pulse TMS (transcranial magnetic stimulation). The study hypothesizes that:

1. The neural mechanisms employed in patients who have different response to TMS stimulation are different. It is hypothesized that patients with no response upon TMS stimulation might have poorer motor function outcome, compared with patients with response upon TMS stimulation.
2. The result of clinical outcome measures is related with TMS measurement.
3. tDCS intervention is beneficial to subjects with poor brain activity. Clinical outcome measures will include a battery of upper limb motor tests such as upper extremity component of the Fugl-Meyer Assessment, Modified Ashworth scale for spasticity, box and block test, and manual muscle testing. Clinical outcome and TMS measurement will be assessed at within 2 weeks, 4-6 weeks and at 6 months post-stroke.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

TMS measurement and clinical outcome measurement will be performed on 119 stroke subjects with upper limb impairment with FMA score at 0-45 at within 1 month from stroke, 6-8 weeks post-stroke, 6 months post-stroke. It is important to know the cortical excitability as well as clinical outcome measurement at the same time point, at different stages of stroke including acute phase, which enables us to know the interaction between brain activity and functional outcome. In addition, studies have shown both TMS (Pennisi et al, 1999) and clinical outcome measurement (FMA)(De Weerdt and Harrison 1985; Bernspang et al. 1987; Feys et al. 2000) are measurable at acute phase after stroke.

Subjects will be recruited from the existing patients on the study physician's cohort of patients and from referrals from attending physicians. During the initial screening visit, FMA will be administered by trained research staff, the questionnaire of MMSE will also be administered by trained research staff for subject's cognitive assessment. Subjects' eligibility will be verified by self-report from the participants as well as their medical records accessed by participating physicians. It will be ascertained that subject fulfills criteria for participation and informed consent will be obtained by study staff. Subjects will be fully briefed in detail regarding the experimental procedure, risk and benefits involved and their responsibilities during the study. Subject will continue with their routine rehabilitation training when they are in the trial.

For patients whose MEP could not be induced by single pulse TMS stimulation, they will be randomly divided into 2 groups with one group receiving 1mA tDCS stimulation for 20 minutes to the primary motor cortex of cortical representation of the hand, while the other group will receive sham stimulation of tDCS.

A research staff supervised by a physician will apply the tDCS to subjects whose MEP could not be induced by TMS stimulation to the corresponding cortex area. Direct current will be transferred by a saline-soaked pair of surface sponge electrode (35cm2) and delivered by a battery-operated, constant current stimulator with a maximum output of 10mA, through a non-metallic conductor rubber electrode. Stimulation will be conducted at the intensity of 1 mA and last for 20 minutes. The anode will be placed over the affected primary motor cortex (M1) of cortical representation of the hand, while the cathode will be used as reference electrode and placed over the forehead of the unaffected side. The same stimulation parameters as tDCS treatment will be employed for the sham stimulation. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation. Current intensity will be increased and decreased gradually (0-1mA) to decrease perception. It is postulated to recruit 20 subjects for each intervention group. The real or sham tDCS intervention will be conducted daily for 10 days after the first and before the second TMS assessment, i.e., between 2 to 6 weeks after the stroke onset. And the real or sham tDCS will be conducted before the daily traditional rehabilitation training, if any.

A research staff supervised by a physician will apply TMS measurement of the cortical excitability and intracortical inhibition/facilitation to the subject. Patients will be seated comfortably and instructed to remain as still as they can. A tight swim cap will be worn by the subject. The vertex will be marked on the cap. Singe pulse TMS was delivered using Magstim Bistim² stimulator via the coil of figure of eight. The coil position was maintained manually by an assistant and the handle of the coil point to posterior with an angel of 45 degree to the sagittal plane. Surface electromyography (EMG) electrodes are attached to the abductor pollicis brevis muscle (APB) for EMG recording. The "hot spot" of the motor evoked potential (MEP) from APB is first identified and marked for both left and right side. This spot will be used for all recordings on that side. The lowest intensity needed to elicit a MEP response of at least 50µV amplitude and that has been elicited in 50% of 8 successive trials will be recorded as resting motor threshold (RMT).

For intracortical inhibition/facilitation recording, a first subthreshold conditioning stimulus (80% of RMT) will be applied, followed by a second suprathreshold stimulus (120% of RMT) with a variable interstimulus interval (ISI). The following ISIs - 2, 3, 4, 6, 9, 10, 12, 15 ms will be used. The percentage of change for each ISI before and after TMS will be calculated from the MEPs and will therefore provide a measure of change in intracortical facilitation and inhibition. Both single- and paired-pulse paradigms will be performed on the affected and unaffected hemisphere.

Clinical outcome measurement includes a battery of upper limb motor tests: Fugl-Meyer Assessment, Modified Ashworth scale for spasticity, manual muscle testing and box and block test, which will be performed by a trained research staff.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

real tDCS

Subjects will receive tDCS stimulation at the intensity of 1 mA and last for 20 minutes. The anode will be placed over the affected primary motor cortex (M1) of cortical representation of the hand, while the cathode will be used as reference electrode and placed over the forehead of the unaffected side.

Group Type EXPERIMENTAL

tDCS

Intervention Type DEVICE

tDCS could deliver either real or sham stimulation.

sham tDCS

Subjects will receive sham tDCS stimulation. The same stimulation parameters as tDCS treatment will be employed for the sham stimulation. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation.

Group Type SHAM_COMPARATOR

tDCS

Intervention Type DEVICE

tDCS could deliver either real or sham stimulation.

no stimulation

Subjects will not received any intervention.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tDCS

tDCS could deliver either real or sham stimulation.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female aged 21-80 years;
2. First ever haemorrhagic or ischaemic hemiplegic stroke less than 1 month prior to study enrollment;
3. Upper extremity impairment of 0-45 out of a maximum score of 66 on the Fugl-Meyer assessment scale.
4. MMSE\>=24.
5. Be able to provide informed consent.

Exclusion Criteria

pregnancy; cardiac pacemakers; orthodontics (braces); metal implant; history of epilepsy; sensorimotor disturbance due to other causes other than stroke; uncontrolled medical conditions including hypertension, diabetes mellitus and unstable angina; major depression and a history of psychotic disorders.
Minimum Eligible Age

21 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National University Hospital, Singapore

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Effie Chew, MD

Role: PRINCIPAL_INVESTIGATOR

National University Hospital, Singapore

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National University Hospital

Singapore, , Singapore

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Singapore

References

Explore related publications, articles, or registry entries linked to this study.

Elsner B, Kugler J, Pohl M, Mehrholz J. Transcranial direct current stimulation (tDCS) for improving activities of daily living, and physical and cognitive functioning, in people after stroke. Cochrane Database Syst Rev. 2020 Nov 11;11(11):CD009645. doi: 10.1002/14651858.CD009645.pub4.

Reference Type DERIVED
PMID: 33175411 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TMS2014/00358

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.